



The Power of Mother Nature Helps Support Joint and Soft Tissue Healing

Pain from osteoarthritis is a common symptom in the decision to seek medical care and is the primary reason for total hip and knee replacements.¹

Clarix Flo is a sterile, micronized amniotic membrane allograft derived from placenta and umbilical cord.

- Facilitates symptom relief associated with many joint and soft tissue conditions²⁻⁶
- Supports safe, clinically impactful outcomes²⁻⁴ without the potential complications associated with repeated steroid injections or unclear benefits of PRP
- Delivers the power of human birth tissue to the site of injury
- Provides an alternative treatment option to surgery



The innate biology of Clarix Flo supports regenerative healing and functional recovery as an adjunct treatment in an array of in-office and surgical applications²⁻⁶

- Plantar fasciitis
- Joint tendinosis
- Soft tissue/nerve repair
- Complex orthopedic reconstruction
- Osteoarthritis
- Rotator Cuff/Labral repair
- Spine conditions

Preserving as Much of Mother Nature as Possible

For over 36 years, our pioneering scientists have focused on understanding the regenerative features of human birth tissue—ultimately identifying HC-HA/PTX3 as a key orchestrator in human birth tissue regenerative healing.⁷⁻¹¹

BioTissue® Surgical human birth tissue products are aseptically processed, devascularized and cell devitalized to deliver the innate properties of human birth tissue to the wound environment.

Clarix Flo



Clarix Flo may be hydrated with saline and injected or applied directly to the injury site.

AS AN ADJUNCT TO SURGERY: helps manage discomfort and facilitate healing, thereby leading to more effective rehabilitation outcomes¹²


AS AN IN-OFFICE INJECTION: helps improve symptoms and function-related soft tissue and joint conditions while avoiding complications common with other injectable treatments^{2,3}

Clarix Flo Micronized Amniotic Membrane Allograft		
CR-FL-25MG	CR-FL-50MG	CR-FL-100MG
25 mg	50 mg	100 mg

In 6 months

From here...

To here.



A representative case of knee osteoarthritis management using adjunctive Clarix Flo.

A 76-year-old male presented with chronic right knee pain and history of diabetes type 1, hypertension, hypercholesterolemia, and coronary artery disease. The pain was constant and severe. Previous treatments had failed. Physical therapy was conducted without success for 1 month.

50mg of the micronized allograft was reconstituted in 3cc of saline and injected within the joint under live ultrasound guidance. Six months after treatment, pain was reduced to 2-4/10 depending on level of activity.

Case Reference: Ramon Castellanos MD - StemCell USA, Miami, FL

Osteoarthritis (OA) is the most common joint disorder in the US.

About 10% of men and 13% of women of 60 years old or older suffer from symptomatic knee OA—and the number will likely increase due to an aging population and higher rates of obesity.¹

1. Zhang Y, Jordan JM. [Published correction appears in *Clin Geriatr Med*. 2013 May;29(2):ix]. *Clin Geriatr Med*. 2010;26(3):355-369. doi:10.1016/j.cger.2010.03.001
2. Garra D, Scott R. AOFAS Annual Meeting 2017.
3. Hanselman AE, Tidwell J, Santrock R. *Foot Ankle Int*. 2015 Feb;36(2):151-8.
4. Swan J. *Surg Technol Int*. 2014;25:73-78.
5. Bennett DS. *Medicine (Baltimore)*. 2019;98(10):e14745.
6. Castellanos R, Tighe S. *Pain Medicine*. 2019;20(11):2283-2291.

7. Tseng SC. *Invest Ophthalmol Vis Sci*. 2016;57(5):ORSFh1-ORSFh8.
8. He H, Li W, Tseng DY, et al. *J Biol Chem*. 2009;284:20136-46.
9. He H, Zhang S, Tighe S, Son J, Tseng SC. *J Biol Chem*. 2013;288:25792-803.
10. Zhang S, He H, Day AJ, et al. *J Biol Chem*. 2012;287:12433-44.
11. Zhang S, Zhu YT, Chen SY, et al. *J Biol Chem*. 2014;289:13531-42.
12. Godshaw B, Wong M, Ojard C, Williams G, Suri M, Jones D. *Ochsner J*. 2019 Winter;19(4):405-409.

biotissue.com/surgical

7300 Corporate Drive, Suite 700, Miami, FL 33126 | 888.296.8858

© 2022 BioTissue, Inc. All rights reserved | US-CLF-2200002



Clarix, Neox, CryoTek, and BioTissue are registered trademarks of TissueTech, Inc. All other trademarks used herein are proprietary to their respective owners. Amniot Medical, Inc.'s products are now part of the BioTissue Surgical brand.

BioTissue Surgical products are authorized under the regulations of the U.S. Food and Drug Administration (FDA) governing the manufacture and distribution of Human Tissue Products. They are marketed as structural tissue products for homologous use and are used by physicians as barriers, wound coverings, conduits, and/or cushions in the treatment of their patients.